Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells

Cancer Lett. 2013 May 1;331(2):220-9. doi: 10.1016/j.canlet.2013.01.004. Epub 2013 Jan 20.

Abstract

We studied the effect of everolimus, an inhibitor of the mammalian target of rapamycin (mTOR) on human gastric cancer cell lines. Cell proliferation in 3 of 8 cell lines was effectively inhibited by everolimus. Basal phosphorylation level of 4E-BP1 (T37/46, T70) was significantly higher in everolimus-sensitive cells than in everolimus-resistant cells. In subcutaneous xenograft model, immunohistochemistry analysis revealed that everolimus-sensitive cells expressed high levels of phospho-4E-BP1 (T37/46). In conclusion, phosphorylation of 4E-BP1 may be a predictive biomarker of everolimus sensitivity in gastric cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing / metabolism*
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Cell Cycle Proteins
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Everolimus
  • Flow Cytometry
  • Humans
  • Immunohistochemistry
  • Phosphoproteins / metabolism*
  • Phosphorylation
  • Sirolimus / analogs & derivatives*
  • Sirolimus / pharmacology
  • Stomach Neoplasms / metabolism
  • Stomach Neoplasms / pathology*
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • Adaptor Proteins, Signal Transducing
  • Antineoplastic Agents
  • Cell Cycle Proteins
  • EIF4EBP1 protein, human
  • Phosphoproteins
  • Everolimus
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sirolimus